Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | QoL benefits of jaktinib for myelofibrosis patients

Jie Jin • 1 Jun 2021
EHA 2021
Anemias Myelofibrosis Myeloproliferative Neoplasms Jaktinib

Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, discussess the benefits of jaktinib treatment for patients with myelofibrosis, higlighting improvements in quality of life (QoL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Jie Jin

0:48
ZGJAK002: jaktinib shows efficacy in myelofibrosis
Jie Jin • 1 Jun 2021
0:50
Management of variant acute promyelocytic leukemia
Jie Jin • 1 Jun 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals